Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Talmadge King, JR., MD

    TitleProfessor
    SchoolUCSF School of Medicine
    DepartmentMedicine
    Address505 Parnassus Ave, Moffitt
    San Francisco CA 94143
    Phone415-476-0909
      Other Positions
      TitleChair, Medicine


       Biography 
       Awards and Honors
      Foundation of the American Thoracic Society 2012Breathing for Life Award
      Gustavus Adolphus College2012Sesquicentennial Award
      American Academy of Arts and Sciences2011 Fellow
      American College of Physicians 2010Master
      Gustavus Alumni Association, Gustavus Adolphus College2008Alumni Citation
      American Thoracic Society2007Trudeau Medal
      Institute of Medicine, National Academy of Sciences2004Member
      Public Advisory Roundtable of the American Thoracic Society2003PAR Excellence Award
      Association of American Physicians1998Member
      California Thoracic Society1998Elected honorary member
      Colorado Thoracic Society, American Lung Association of Colorado1998Member. Colorado Pulmonary Hall of Fame
      The Fleischner Society 1997Member
      Western Association of Physicians 1993Member
      American Lung Association of Colorado1992James J. Waring Award For Outstanding Leadership in the Treatment of Lung Disease
      American College of Physicians 1986Fellow
      American College of Chest Physicians1984Fellow
      Alumni Association, Gustavus Adolphus College1980First Decade Award for Early Achievement
      Gustavus Adolphus College1970Guild of St. Ansger Honor Society

       Overview 
       Overview
      Dr. Talmadge E. King, Jr. is chair of the Department of Medicine at the University of California, San Francisco where he oversees a department of more than 550 full-time faculty, over 500 volunteer clinical faculty, 180 residents, 238 fellows and over 1000 support staff. His focus in patient care is interstitial lung diseases, in particular idiopathic pulmonary fibrosis, sarcoidosis, connective tissue disease, hypersensitivity pneumonitis, drug-induced lung fibrosis and other rare diffuse lung disorders. King's research interests include pathogenesis, diagnosis and management of inflammatory and immunologic lung disease. He has co-authored eight books including the acclaimed reference book, "Interstitial Lung Disease," now in its fourth edition.

      King earned a medical degree at Harvard Medical School, followed by a residency at Emory University Affiliated Hospitals in Atlanta, Ga. and a pulmonary fellowship at the University of Colorado Health Sciences Center in Denver. He is a member of the American Academy of Arts and Sciences, Institute of Medicine, National Academy of Sciences, Association of American Physicians, American Clinical and Climatological Association and Fleischner Society and is a master of the American College of Physicians and fellow he American College of Chest Physicians. He holds the Julius R. Krevans Distinguished Professorship in Internal Medicine and won the 2007 Trudeau Medal, the highest honor of the American Lung Association and American Thoracic Society.

      Research Interests

      His overall focus has been on understanding the pathogenesis, diagnosis and management of inflammatory and immunology lung injury. Another aim is to develop and evaluate methods that can serially identify the presence and extent of disease activity in these patients.


       ORNG Applications 
       Websites
       In The News
       Awarded Grants
       More Info

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29; 370(22):2093-101.
        View in: PubMed
      2. King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29; 370(22):2083-92.
        View in: PubMed
      3. Valeyre D, Albera C, Bradford WZ, Costabel U, King TE, Leff JA, Noble PW, Sahn SA, du Bois RM. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology. 2014 Jul; 19(5):740-7.
        View in: PubMed
      4. King TE, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med. 2014 Apr 1; 189(7):825-31.
        View in: PubMed
      5. Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, Koth LL, King TE, Collard HR. Predicting Survival Across Chronic Interstitial Lung Disease: The ILD-GAP Model. Chest. 2014 Apr 1; 145(4):723-8.
        View in: PubMed
      6. Blackwell TS, Tager AM, Borok Z, Moore BB, Schwartz DA, Anstrom KJ, Bar-Joseph Z, Bitterman P, Blackburn MR, Bradford W, Brown KK, Chapman HA, Collard HR, Cosgrove GP, Deterding R, Doyle R, Flaherty KR, Garcia CK, Hagood JS, Henke CA, Herzog E, Hogaboam CM, Horowitz JC, King TE, Loyd JE, Lawson WE, Marsh CB, Noble PW, Noth I, Sheppard D, Olsson J, Ortiz LA, O'Riordan TG, Oury TD, Raghu G, Roman J, Sime PJ, Sisson TH, Tschumperlin D, Violette SM, Weaver TE, Wells RG, White ES, Kaminski N, Martinez FJ, Wynn TA, Thannickal VJ, Eu JP. Future Directions in Idiopathic Pulmonary Fibrosis Research. An NHLBI Workshop Report. Am J Respir Crit Care Med. 2014 Jan 15; 189(2):214-22.
        View in: PubMed
      7. Assayag D, Lee JS, King TE. Rheumatoid arthritis associated interstitial lung disease: a review. Medicina (B Aires). 2014; 74(2):158-65.
        View in: PubMed
      8. Assayag D, Lubin M, Lee JS, King TE, Collard HR, Ryerson CJ. Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. Respirology. 2014 May; 19(4):493-500.
        View in: PubMed
      9. Swigris JJ, Streiner DL, Brown KK, Belkin A, Green KE, Wamboldt FS. Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis. Respir Med. 2014 Jan; 108(1):181-8.
        View in: PubMed
      10. du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE. 6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2014 May; 43(5):1421-9.
        View in: PubMed
      11. Assayag D, Elicker BM, Urbania TH, Colby TV, Kang BH, Ryu JH, King TE, Collard HR, Kim DS, Lee JS. Rheumatoid Arthritis-associated Interstitial Lung Disease: Radiologic Identification of Usual Interstitial Pneumonia Pattern. Radiology. 2014 Feb; 270(2):583-8.
        View in: PubMed
      12. Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013 Sep 15; 188(6):733-48.
        View in: PubMed
      13. Mooney JJ, Elicker BM, Urbania TH, Agarwal MR, Ryerson CJ, Nguyen ML, Woodruff PG, Jones KD, Collard HR, King TE, Koth LL. Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. Chest. 2013 Aug; 144(2):586-92.
        View in: PubMed
      14. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013; 14:73.
        View in: PubMed
      15. Ryerson CJ, Hartman T, Elicker BM, Ley B, Lee JS, Abbritti M, Jones KD, King TE, Ryu J, Collard HR. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013 Jul; 144(1):234-40.
        View in: PubMed
      16. Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013 Jul; 1(5):369-76.
        View in: PubMed
      17. Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK. Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2013 Jun 1; 187(11):1272.
        View in: PubMed
      18. Han MK, Bach DS, Hagan PG, Yow E, Flaherty KR, Toews GB, Anstrom KJ, Martinez FJ. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest. 2013 Jun; 143(6):1699-708.
        View in: PubMed
      19. Ryerson CJ, Urbania TH, Richeldi L, Mooney JJ, Lee JS, Jones KD, Elicker BM, Koth LL, King TE, Wolters PJ, Collard HR. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2013 Sep; 42(3):750-7.
        View in: PubMed
      20. Lee JS, Kim EJ, Lynch KL, Elicker B, Ryerson CJ, Katsumoto TR, Shum AK, Wolters PJ, Cerri S, Richeldi L, Jones KD, King TE, Collard HR. Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respir Med. 2013 Feb; 107(2):249-55.
        View in: PubMed
      21. Selman M, Pardo A, King TE. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med. 2012 Aug 15; 186(4):314-24.
        View in: PubMed
      22. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012 May 24; 366(21):1968-77.
        View in: PubMed
      23. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE, Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012 May 15; 156(10):684-91.
        View in: PubMed
      24. Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012 Jul 1; 186(1):88-95.
        View in: PubMed
      25. Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012 May 15; 185(10):1044-8.
        View in: PubMed
      26. Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, Elicker BM, Jones KD, King TE, Ryu JH, Collard HR. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax. 2012 May; 67(5):407-11.
        View in: PubMed
      27. King TE, Collard HR, Richeldi L. Interstitial lung diseases. Preface. Clin Chest Med. 2012 Mar; 33(1):xiii.
        View in: PubMed
      28. Lee JS, Song JW, Wolters PJ, Elicker BM, King TE, Kim DS, Collard HR. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J. 2012 Feb; 39(2):352-8.
        View in: PubMed
      29. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE, Lancaster L, Noble PW, Sahn SA, Thomeer M, Valeyre D, Wells AU. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011 Dec 15; 184(12):1382-9.
        View in: PubMed
      30. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Aug 15; 184(4):459-66.
        View in: PubMed
      31. King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011 Dec 3; 378(9807):1949-61.
        View in: PubMed
      32. Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, King TE, Collard HR. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Dec 15; 184(12):1390-4.
        View in: PubMed
      33. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011 May 21; 377(9779):1760-9.
        View in: PubMed
      34. King TE, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Jul 1; 184(1):92-9.
        View in: PubMed
      35. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 Mar 15; 183(6):788-824.
        View in: PubMed
      36. King TE. Smoking and subclinical interstitial lung disease. N Engl J Med. 2011 Mar 10; 364(10):968-70.
        View in: PubMed
      37. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011 May 1; 183(9):1231-7.
        View in: PubMed
      38. Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Feb 15; 183(4):431-40.
        View in: PubMed
      39. Castriotta RJ, Eldadah BA, Foster WM, Halter JB, Hazzard WR, Kiley JP, King TE, Horne FM, Nayfield SG, Reynolds HY, Schmader KE, Toews GB, High KP. Workshop on idiopathic pulmonary fibrosis in older adults. Chest. 2010 Sep; 138(3):693-703.
        View in: PubMed
      40. Arjomandi M, Seward J, Gotway MB, Nishimura S, Fulton GP, Thundiyil J, King TE, Harber P, Balmes JR. Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility. J Occup Environ Med. 2010 Jun; 52(6):647-52.
        View in: PubMed
      41. Collard HR, Calfee CS, Wolters PJ, Song JW, Hong SB, Brady S, Ishizaka A, Jones KD, King TE, Matthay MA, Kim DS. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010 Jul; 299(1):L3-7.
        View in: PubMed
      42. Kinder BW, Shariat C, Collard HR, Koth LL, Wolters PJ, Golden JA, Panos RJ, King TE. Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function. Lung. 2010 Apr; 188(2):143-9.
        View in: PubMed
      43. Lee JS, Collard HR, Raghu G, Sweet MP, Hays SR, Campos GM, Golden JA, King TE. Does chronic microaspiration cause idiopathic pulmonary fibrosis? Am J Med. 2010 Apr; 123(4):304-11.
        View in: PubMed
      44. Levinson W, King TE, Goldman L, Goroll AH, Kessler B. Clinical decisions. American Board of Internal Medicine maintenance of certification program. N Engl J Med. 2010 Mar 11; 362(10):948-52.
        View in: PubMed
      45. Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Van Uden JH, Lee JS, King TE, Collard HR. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010 Jun; 35(6):1322-8.
        View in: PubMed
      46. Swigris JJ, Wamboldt FS, Behr J, du Bois RM, King TE, Raghu G, Brown KK. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax. 2010 Feb; 65(2):173-7.
        View in: PubMed
      47. Kim EJ, Collard HR, King TE. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest. 2009 Nov; 136(5):1397-405.
        View in: PubMed
      48. Swigris JJ, Brown KK, Behr J, du Bois RM, King TE, Raghu G, Wamboldt FS. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med. 2010 Feb; 104(2):296-304.
        View in: PubMed
      49. Buckley JD, Addrizzo-Harris DJ, Clay AS, Curtis JR, Kotloff RM, Lorin SM, Murin S, Sessler CN, Rogers PL, Rosen MJ, Spevetz A, King TE, Malhotra A, Parsons PE. Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine. Am J Respir Crit Care Med. 2009 Aug 15; 180(4):290-5.
        View in: PubMed
      50. Raghu G, King TE, Behr J, Brown KK, du Bois RM, Leconte I, Roux S, Swigris J. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J. 2010 Jan; 35(1):118-23.
        View in: PubMed
      51. de Kleijn WP, Elfferich MD, De Vries J, Jonker GJ, Lower EE, Baughman RP, King TE, Drent M. Fatigue in sarcoidosis: American versus Dutch patients. Sarcoidosis Vasc Diffuse Lung Dis. 2009 Jul; 26(2):92-7.
        View in: PubMed
      52. King TE, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, du Bois RM. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009 Jul 18; 374(9685):222-8.
        View in: PubMed
      53. Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI, King TE. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest. 2009 Jun; 135(6):1557-63.
        View in: PubMed
      54. King TE. Bosentan for idiopathic pulmonary fibrosis. Curr Opin Investig Drugs. 2008 Nov; 9(11):1171-9.
        View in: PubMed
      55. Kinder BW, King TE. Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease. Am J Respir Crit Care Med. 2008 Jun 1; 177(11):1292-3; author reply 1293.
        View in: PubMed
      56. Collard HR, King TE. Idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia should stay separate. Eur Respir J. 2008 May; 31(5):1141-2; author reply 1142-3.
        View in: PubMed
      57. Travis WD, Hunninghake G, King TE, Lynch DA, Colby TV, Galvin JR, Brown KK, Chung MP, Cordier JF, du Bois RM, Flaherty KR, Franks TJ, Hansell DM, Hartman TE, Kazerooni EA, Kim DS, Kitaichi M, Koyama T, Martinez FJ, Nagai S, Midthun DE, Müller NL, Nicholson AG, Raghu G, Selman M, Wells A. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med. 2008 Jun 15; 177(12):1338-47.
        View in: PubMed
      58. Wilson JW, du Bois RM, King TE. Challenges in pulmonary fibrosis: 8--The need for an international registry for idiopathic pulmonary fibrosis. Thorax. 2008 Mar; 63(3):285-7.
        View in: PubMed
      59. Kinder BW, Brown KK, Schwarz MI, Ix JH, Kervitsky A, King TE. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest. 2008 Jan; 133(1):226-32.
        View in: PubMed
      60. du Bois R, King TE. Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate. Thorax. 2007 Nov; 62(11):1008-12.
        View in: PubMed
      61. King TE, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stähler G, Leconte I, Roux S, Raghu G. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008 Jan 1; 177(1):75-81.
        View in: PubMed
      62. Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, King TE, Golden JA. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med. 2008 Jan; 102(1):150-5.
        View in: PubMed
      63. Kinder BW, Freemer MM, King TE, Lum RF, Nititham J, Taylor K, Edberg JC, Bridges SL, Criswell LA. Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus. Arthritis Rheum. 2007 Aug; 56(8):2679-86.
        View in: PubMed
      64. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kondoh Y, Lynch DA, Müller-Quernheim J, Myers JL, Nicholson AG, Selman M, Toews GB, Wells AU, Martinez FJ. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007 Oct 1; 176(7):636-43.
        View in: PubMed
      65. Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B, Jones KD, King TE. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med. 2007 Oct 1; 176(7):691-7.
        View in: PubMed
      66. Gotway MB, Freemer MM, King TE. Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias. Thorax. 2007 Jun; 62(6):546-53.
        View in: PubMed
      67. Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J, Gaxiola M, Pérez-Padilla R, Navarro C, Richards T, Dauber J, King TE, Pardo A, Kaminski N. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One. 2007; 2(5):e482.
        View in: PubMed
      68. Collard HR, Loyd JE, King TE, Lancaster LH. Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. Respir Med. 2007 Sep; 101(9):2011-6.
        View in: PubMed
      69. Portnoy J, Veraldi KL, Schwarz MI, Cool CD, Curran-Everett D, Cherniack RM, King TE, Brown KK. Respiratory bronchiolitis-interstitial lung disease: long-term outcome. Chest. 2007 Mar; 131(3):664-71.
        View in: PubMed
      70. Calfee CS, Shah SJ, Wolters PJ, Saint S, King TE. Clinical problem-solving. Anchors away. N Engl J Med. 2007 Feb 1; 356(5):504-9.
        View in: PubMed
      71. Flaherty KR, Andrei AC, King TE, Raghu G, Colby TV, Wells A, Bassily N, Brown K, du Bois R, Flint A, Gay SE, Gross BH, Kazerooni EA, Knapp R, Louvar E, Lynch D, Nicholson AG, Quick J, Thannickal VJ, Travis WD, Vyskocil J, Wadenstorer FA, Wilt J, Toews GB, Murray S, Martinez FJ. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med. 2007 May 15; 175(10):1054-60.
        View in: PubMed
      72. Zamora AC, Collard HR, Wolters PJ, Webb WR, King TE. Neurofibromatosis-associated lung disease: a case series and literature review. Eur Respir J. 2007 Jan; 29(1):210-4.
        View in: PubMed
      73. Kinder BW, Collard HR, King TE. Anticoagulant therapy and idiopathic pulmonary fibrosis. Chest. 2006 Jul; 130(1):302-3.
        View in: PubMed
      74. Kim DS, Collard HR, King TE. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc. 2006 Jun; 3(4):285-92.
        View in: PubMed
      75. Walter N, Collard HR, King TE. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc. 2006 Jun; 3(4):330-8.
        View in: PubMed
      76. Perez RL, Kimani AP, King TE, Aguayo SM, Roman J. Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis. Respiration. 2007; 74(3):297-303.
        View in: PubMed
      77. King T, Kavanagh AM, Jolley D, Turrell G, Crawford D. Weight and place: a multilevel cross-sectional survey of area-level social disadvantage and overweight/obesity in Australia. Int J Obes (Lond). 2006 Feb; 30(2):281-7.
        View in: PubMed
      78. Wesson DE, King TE, Todd RF, Torres EA, Hellmann DB, Flack JM, Dubose TD, Schuster VL. Achieving diversity in academic internal medicine: recommendations for leaders. Am J Med. 2006 Jan; 119(1):76-81.
        View in: PubMed
      79. Girod CE, King TE. COPD: a dust-induced disease? Chest. 2005 Oct; 128(4):3055-64.
        View in: PubMed
      80. Shah NR, Noble P, Jackson RM, King TE, Nathan SD, Padilla M, Raghu G, Rhodes MB, Schwarz M, Tino G, Dubois RW. A critical assessment of treatment options for idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005 Oct; 22(3):167-74.
        View in: PubMed
      81. Freemer MM, King TE, Criswell LA. Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus. Ann Rheum Dis. 2006 May; 65(5):581-4.
        View in: PubMed
      82. King TE. Idiopathic interstitial pneumonias: translating our current understanding into novel therapies. Exp Lung Res. 2005 Sep; 31 Suppl 1:41-6.
        View in: PubMed
      83. Lynch DA, Travis WD, Müller NL, Galvin JR, Hansell DM, Grenier PA, King TE. Idiopathic interstitial pneumonias: CT features. Radiology. 2005 Jul; 236(1):10-21.
        View in: PubMed
      84. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE, Flaherty KR, Schwartz DA, Noble PW, Raghu G, Brown KK. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005 Jun 21; 142(12 Pt 1):963-7.
        View in: PubMed
      85. Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, Raghu G, King TE, Bradford WZ, Schwartz DA, Richard Webb W. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005 Aug 15; 172(4):488-93.
        View in: PubMed
      86. King TE. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med. 2005 Aug 1; 172(3):268-79.
        View in: PubMed
      87. King TE, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, Schwartz DA. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest. 2005 Jan; 127(1):171-7.
        View in: PubMed
      88. King TE, Wheeler MB. Inequality in health care: unjust, inhumane, and unattended! Ann Intern Med. 2004 Nov 16; 141(10):815-7.
        View in: PubMed
      89. Flaherty KR, King TE, Raghu G, Lynch JP, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, Murray S, Lama VN, Gay SE, Martinez FJ. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med. 2004 Oct 15; 170(8):904-10.
        View in: PubMed
      90. Collard HR, Ryu JH, Douglas WW, Schwarz MI, Curran-Everett D, King TE, Brown KK. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest. 2004 Jun; 125(6):2169-74.
        View in: PubMed
      91. Vourlekis JS, Schwarz MI, Cherniack RM, Curran-Everett D, Cool CD, Tuder RM, King TE, Brown KK. The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. Am J Med. 2004 May 15; 116(10):662-8.
        View in: PubMed
      92. King TE, Dickinson TA, DuBose TD, Flack JM, Hellmann DB, Pamies RJ, Todd RF, Torres EA, Wesson DE. The case for diversity in academic internal medicine. Am J Med. 2004 Feb 15; 116(4):284-9.
        View in: PubMed
      93. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004 Jan 8; 350(2):125-33.
        View in: PubMed
      94. King TE. Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management. Trans Am Clin Climatol Assoc. 2004; 115:43-76; discussion 76-8.
        View in: PubMed
      95. Hunninghake GW, Lynch DA, Galvin JR, Gross BH, Müller N, Schwartz DA, King TE, Lynch JP, Hegele R, Waldron J, Colby TV, Hogg JC. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest. 2003 Oct; 124(4):1215-23.
        View in: PubMed
      96. King TE. Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic. Semin Respir Crit Care Med. 2003 Oct; 24(5):567-76.
        View in: PubMed
      97. Morris DG, Jasmer RM, Huang L, Gotway MB, Nishimura S, King TE. Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence. Chest. 2003 Sep; 124(3):929-35.
        View in: PubMed
      98. Collard HR, King TE, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003 Sep 1; 168(5):538-42.
        View in: PubMed
      99. Collard HR, King TE. Demystifying idiopathic interstitial pneumonia. Arch Intern Med. 2003 Jan 13; 163(1):17-29.
        View in: PubMed
      100. Inoue Y, King TE, Barker E, Daniloff E, Newman LS. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2002 Sep 1; 166(5):765-73.
        View in: PubMed
      101. Crystal RG, Bitterman PB, Mossman B, Schwarz MI, Sheppard D, Almasy L, Chapman HA, Friedman SL, King TE, Leinwand LA, Liotta L, Martin GR, Schwartz DA, Schultz GS, Wagner CR, Musson RA. Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med. 2002 Jul 15; 166(2):236-46.
        View in: PubMed
      102. King TE. Nonspecific interstitial pneumonia and systemic sclerosis. Am J Respir Crit Care Med. 2002 Jun 15; 165(12):1578-9.
        View in: PubMed
      103. King TE. Racial disparities in clinical trials. N Engl J Med. 2002 May 2; 346(18):1400-2.
        View in: PubMed
      104. Vourlekis JS, Schwarz MI, Cool CD, Tuder RM, King TE, Brown KK. Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis. Am J Med. 2002 Apr 15; 112(6):490-3.
        View in: PubMed
      105. Greene KE, King TE, Kuroki Y, Bucher-Bartelson B, Hunninghake GW, Newman LS, Nagae H, Mason RJ. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J. 2002 Mar; 19(3):439-46.
        View in: PubMed
      106. Freemer M, King TE. The ACCESS study: characterization of sarcoidosis in the United States. Am J Respir Crit Care Med. 2001 Nov 15; 164(10 Pt 1):1754-5.
        View in: PubMed
      107. Collard HR, King TE. Lung biopsy in patients with usual interstitial pneumonia. Eur Respir J. 2001 Nov; 18(5):895-8.
        View in: PubMed
      108. Martinez JA, Nishimura C, Guatura SB, Sato E, King TE. Elevation of soluble interleukin-2 receptor levels in the bronchoalveolar lavage from patients with systemic sclerosis. Rheumatol Int. 2001 Nov; 21(3):122-6.
        View in: PubMed
      109. King TE, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001 Oct 1; 164(7):1171-81.
        View in: PubMed
      110. King TE, Schwarz MI, Brown K, Tooze JA, Colby TV, Waldron JA, Flint A, Thurlbeck W, Cherniack RM. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med. 2001 Sep 15; 164(6):1025-32.
        View in: PubMed
      111. Collard HR, King TE. The clinical significance of histopathologic subgroups in idiopathic interstitial pneumonia: is surgical lung biopsy essential? Semin Respir Crit Care Med. 2001 Aug; 22(4):347-56.
        View in: PubMed
      112. Hunninghake GW, Zimmerman MB, Schwartz DA, King TE, Lynch J, Hegele R, Waldron J, Colby T, Müller N, Lynch D, Galvin J, Gross B, Hogg J, Toews G, Helmers R, Cooper JA, Baughman R, Strange C, Millard M. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001 Jul 15; 164(2):193-6.
        View in: PubMed
      113. Collard HR, King TE. Treatment of idiopathic pulmonary fibrosis: the rise and fall of corticosteroids. Am J Med. 2001 Mar; 110(4):326-8.
        View in: PubMed
      114. Costabel U, King TE. International consensus statement on idiopathic pulmonary fibrosis. Eur Respir J. 2001 Feb; 17(2):163-7.
        View in: PubMed
      115. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001 Jan 16; 134(2):136-51.
        View in: PubMed
      116. Vourlekis JS, Brown KK, Cool CD, Young DA, Cherniack RM, King TE, Schwarz MI. Acute interstitial pneumonitis. Case series and review of the literature. Medicine (Baltimore). 2000 Nov; 79(6):369-78.
        View in: PubMed
      117. King TE. Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis. N Engl J Med. 2000 Mar 30; 342(13):974-5.
        View in: PubMed
      118. King TE, Brunetta P. Racial disparity in rates of surgery for lung cancer. N Engl J Med. 1999 Oct 14; 341(16):1231-3.
        View in: PubMed
      119. Rose CS, Martyny JW, Newman LS, Milton DK, King TE, Beebe JL, McCammon JB, Hoffman RE, Kreiss K. "Lifeguard lung": endemic granulomatous pneumonitis in an indoor swimming pool. Am J Public Health. 1998 Dec; 88(12):1795-800.
        View in: PubMed
      120. King TE. Update in pulmonary medicine. Ann Intern Med. 1998 Nov 15; 129(10):806-12.
        View in: PubMed
      121. Cohen AJ, King TE, Gilman LB, Magill-Solc C, Miller YE. High expression of neutral endopeptidase in idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells. Am J Respir Crit Care Med. 1998 Nov; 158(5 Pt 1):1593-9.
        View in: PubMed
      122. Uh ST, Inoue Y, King TE, Chan ED, Newman LS, Riches DW. Morphometric analysis of insulin-like growth factor-I localization in lung tissues of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998 Nov; 158(5 Pt 1):1626-35.
        View in: PubMed
      123. Fontenot A, Jennings C, King TE. Pulmonary opacities and glomerulonephritis in a 15-year-old boy. Chest. 1998 Feb; 113(2):525-7.
        View in: PubMed
      124. Crausman RS, King TE. Pulmonary vascular involvement in pulmonary histiocytosis X. Chest. 1997 Dec; 112(6):1714.
        View in: PubMed
      125. Martinez JA, King TE, Brown K, Jennings CA, Borish L, Mortenson RL, Khan TZ, Bost TW, Riches DW. Increased expression of the interleukin-10 gene by alveolar macrophages in interstitial lung disease. Am J Physiol. 1997 Sep; 273(3 Pt 1):L676-83.
        View in: PubMed
      126. Tomioka R, King TE. Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease. Am J Respir Crit Care Med. 1997 Mar; 155(3):1011-20.
        View in: PubMed
      127. Jennings CA, King TE, Tuder R, Cherniack RM, Schwarz MI. Diffuse alveolar hemorrhage with underlying isolated, pauciimmune pulmonary capillaritis. Am J Respir Crit Care Med. 1997 Mar; 155(3):1101-9.
        View in: PubMed
      128. Inoue Y, King TE, Tinkle SS, Dockstader K, Newman LS. Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders. Am J Pathol. 1996 Dec; 149(6):2037-54.
        View in: PubMed
      129. King TE. A lung biopsy is necessary in the management of ANCA-positive patients with chest roentgenographic abnormalities. Sarcoidosis Vasc Diffuse Lung Dis. 1996 Oct; 13(3):238-40.
        View in: PubMed
      130. Fitzgerald JE, King TE, Lynch DA, Tuder RM, Schwarz MI. Diffuse panbronchiolitis in the United States. Am J Respir Crit Care Med. 1996 Aug; 154(2 Pt 1):497-503.
        View in: PubMed
      131. Crausman RS, Jennings CA, Mortenson RL, Ackerson LM, Irvin CG, King TE. Lymphangioleiomyomatosis: the pathophysiology of diminished exercise capacity. Am J Respir Crit Care Med. 1996 Apr; 153(4 Pt 1):1368-76.
        View in: PubMed
      132. Inoue Y, Cornebise M, Daniloff E, Lloyd J, Tinkle S, King TE, Newman LS. Mast cell-associated basic fibroblast growth factor in the fibrotic response to environmental toxins. The Beryllium Model. Chest. 1996 Mar; 109(3 Suppl):43S-44S.
        View in: PubMed
      133. Crausman RS, Jennings CA, Tuder RM, Ackerson LM, Irvin CG, King TE. Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology. Am J Respir Crit Care Med. 1996 Jan; 153(1):426-35.
        View in: PubMed
      134. Crausman RS, Lynch DA, Mortenson RL, King TE, Irvin CG, Hale VA, Newell JD. Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomyomatosis. Chest. 1996 Jan; 109(1):131-7.
        View in: PubMed
      135. Bernstein SM, Newell JD, Adamczyk D, Mortenson RL, King TE, Lynch DA. How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis? Am J Respir Crit Care Med. 1995 Dec; 152(6 Pt 1):2138-43.
        View in: PubMed
      136. Ohta K, Mortenson RL, Clark RA, Hirose N, King TE. Immunohistochemical identification and characterization of smooth muscle-like cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1995 Nov; 152(5 Pt 1):1659-65.
        View in: PubMed
      137. Lynch DA, Newell JD, Logan PM, King TE, Müller NL. Can CT distinguish hypersensitivity pneumonitis from idiopathic pulmonary fibrosis? AJR Am J Roentgenol. 1995 Oct; 165(4):807-11.
        View in: PubMed
      138. McCormack FX, King TE, Bucher BL, Nielsen L, Mason RJ, McCormac FX. Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1995 Aug; 152(2):751-9.
        View in: PubMed
      139. Crystal RG, Mastrangeli A, Sanders A, Cooke J, King T, Gilbert F, Henschke C, Pascal W, Herena J, Harvey BG, et al. Evaluation of repeat administration of a replication deficient, recombinant adenovirus containing the normal cystic fibrosis transmembrane conductance regulator cDNA to the airways of individuals with cystic fibrosis. Hum Gene Ther. 1995 May; 6(5):667-703.
        View in: PubMed
      140. Janson RW, Hance KR, King TE. Human alveolar macrophages produce predominantly the 35-kD pro-forms of interleukin-1 alpha and interleukin-1 beta when stimulated with lipopolysaccharide. Am J Respir Crit Care Med. 1995 May; 151(5):1613-20.
        View in: PubMed
      141. Cherniack RM, Colby TV, Flint A, Thurlbeck WM, Waldron JA, Ackerson L, Schwarz MI, King TE. Correlation of structure and function in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1995 Apr; 151(4):1180-8.
        View in: PubMed
      142. King TE. BOOP: an important cause of migratory pulmonary infiltrates? Eur Respir J. 1995 Feb; 8(2):193-5.
        View in: PubMed
      143. Forrester JM, Wang Y, Ricalton N, Fitzgerald JE, Loveless J, Newman LS, King TE, Kotzin BL. TCR expression of activated T cell clones in the lungs of patients with pulmonary sarcoidosis. J Immunol. 1994 Nov 1; 153(9):4291-302.
        View in: PubMed
      144. Newman LS, Bobka C, Schumacher B, Daniloff E, Zhen B, Mroz MM, King TE. Compartmentalized immune response reflects clinical severity of beryllium disease. Am J Respir Crit Care Med. 1994 Jul; 150(1):135-42.
        View in: PubMed
      145. Cohen AJ, King TE, Downey GP. Rapidly progressive bronchiolitis obliterans with organizing pneumonia. Am J Respir Crit Care Med. 1994 Jun; 149(6):1670-5.
        View in: PubMed
      146. Garg K, Lynch DA, Newell JD, King TE. Proliferative and constrictive bronchiolitis: classification and radiologic features. AJR Am J Roentgenol. 1994 Apr; 162(4):803-8.
        View in: PubMed
      147. Wade JF, King TE. Dyspnea, cough, and interstitial lung disease in a 32-year-old smoker. Chest. 1994 Jan; 105(1):265-7.
        View in: PubMed
      148. Carré PC, King TE, Mortensen R, Riches DW. Cryptogenic organizing pneumonia: increased expression of interleukin-8 and fibronectin genes by alveolar macrophages. Am J Respir Cell Mol Biol. 1994 Jan; 10(1):100-5.
        View in: PubMed
      149. King TE. Overview of bronchiolitis. Clin Chest Med. 1993 Dec; 14(4):607-10.
        View in: PubMed
      150. King TE. Respiratory bronchiolitis-associated interstitial lung disease. Clin Chest Med. 1993 Dec; 14(4):693-8.
        View in: PubMed
      151. Kraft M, Mortenson RL, Colby TV, Newman L, Waldron JA, King TE. Cryptogenic constrictive bronchiolitis. A clinicopathologic study. Am Rev Respir Dis. 1993 Oct; 148(4 Pt 1):1093-101.
        View in: PubMed
      152. Wade JF, King TE. Infiltrative and interstitial lung disease in the elderly patient. Clin Chest Med. 1993 Sep; 14(3):501-21.
        View in: PubMed
      153. Janson RW, King TE, Hance KR, Arend WP. Enhanced production of IL-1 receptor antagonist by alveolar macrophages from patients with interstitial lung disease. Am Rev Respir Dis. 1993 Aug; 148(2):495-503.
        View in: PubMed
      154. Schwarz MI, Mortenson RL, Colby TV, Waldron JA, Lynch DA, Hutt MP, Cherniack RM, King TE. Pulmonary capillaritis. The association with progressive irreversible airflow limitation and hyperinflation. Am Rev Respir Dis. 1993 Aug; 148(2):507-11.
        View in: PubMed
      155. Forrester JM, Newman LS, Wang Y, King TE, Kotzin BL. Clonal expansion of lung V delta 1+ T cells in pulmonary sarcoidosis. J Clin Invest. 1993 Jan; 91(1):292-300.
        View in: PubMed
      156. King TE. Restrictive lung disease in pregnancy. Clin Chest Med. 1992 Dec; 13(4):607-22.
        View in: PubMed
      157. Buschman DL, Gamsu G, Waldron JA, Klein JS, King TE. Chronic hypersensitivity pneumonitis: use of CT in diagnosis. AJR Am J Roentgenol. 1992 Nov; 159(5):957-60.
        View in: PubMed
      158. Aguayo SM, Miller YE, Waldron JA, Bogin RM, Sunday ME, Staton GW, Beam WR, King TE. Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. N Engl J Med. 1992 Oct 29; 327(18):1285-8.
        View in: PubMed
      159. Hyde DM, King TE, McDermott T, Waldron JA, Colby TV, Thurlbeck WM, Flint WM, Ackerson L, Cherniack RM. Idiopathic pulmonary fibrosis. Quantitative assessment of lung pathology. Comparison of a semiquantitative and a morphometric histopathologic scoring system. Am Rev Respir Dis. 1992 Oct; 146(4):1042-7.
        View in: PubMed
      160. Low RB, Giancola MS, King TE, Chapitis J, Vacek P, Davis GS. Serum and bronchoalveolar lavage of N-terminal type III procollagen peptides in idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1992 Sep; 146(3):701-6.
        View in: PubMed
      161. Lynch DA, Rose CS, Way D, King TE. Hypersensitivity pneumonitis: sensitivity of high-resolution CT in a population-based study. AJR Am J Roentgenol. 1992 Sep; 159(3):469-72.
        View in: PubMed
      162. King TE, Mortenson RL. Cryptogenic organizing pneumonitis. The North American experience. Chest. 1992 Jul; 102(1 Suppl):8S-13S.
        View in: PubMed
      163. King TE, Mortenson RL. Bronchoalveolar lavage in patients with connective tissue disease. J Thorac Imaging. 1992 Jun; 7(3):26-48.
        View in: PubMed
      164. Aguayo SM, King TE, Kane MA, Sherritt KM, Silvers W, Nett LM, Petty TL, Miller YE. Urinary levels of bombesin-like peptides in asymptomatic cigarette smokers: a potential risk marker for smoking-related diseases. Cancer Res. 1992 May 1; 52(9 Suppl):2727s-2731s.
        View in: PubMed
      165. Kulwiec EL, Lynch DA, Aguayo SM, Schwarz MI, King TE. Imaging of pulmonary histiocytosis X. Radiographics. 1992 May; 12(3):515-26.
        View in: PubMed
      166. Carré PC, Mortenson RL, King TE, Noble PW, Sable CL, Riches DW. Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis. A potential mechanism for the recruitment and activation of neutrophils in lung fibrosis. J Clin Invest. 1991 Dec; 88(6):1802-10.
        View in: PubMed
      167. Hanley ME, King TE, Schwarz MI, Watters LC, Shen AS, Cherniack RM. The impact of smoking on mechanical properties of the lungs in idiopathic pulmonary fibrosis and sarcoidosis. Am Rev Respir Dis. 1991 Nov; 144(5):1102-6.
        View in: PubMed
      168. Cherniack RM, Colby TV, Flint A, Thurlbeck WM, Waldron J, Ackerson L, King TE. Quantitative assessment of lung pathology in idiopathic pulmonary fibrosis. The BAL Cooperative Group Steering Committee. Am Rev Respir Dis. 1991 Oct; 144(4):892-900.
        View in: PubMed
      169. Alford CE, King TE, Campbell PA. Role of transferrin, transferrin receptors, and iron in macrophage listericidal activity. J Exp Med. 1991 Aug 1; 174(2):459-66.
        View in: PubMed
      170. McCormack FX, King TE, Voelker DR, Robinson PC, Mason RJ. Idiopathic pulmonary fibrosis. Abnormalities in the bronchoalveolar lavage content of surfactant protein A. Am Rev Respir Dis. 1991 Jul; 144(1):160-6.
        View in: PubMed
      171. King TE. Diagnostic advances in idiopathic pulmonary fibrosis. Chest. 1991 Jul; 100(1):238-41.
        View in: PubMed
      172. Leslie K, King TE, Low R. Smooth muscle actin is expressed by air space fibroblast-like cells in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis. Chest. 1991 Mar; 99(3 Suppl):47S-48S.
        View in: PubMed
      173. Shaw RJ, Benedict SH, Clark RA, King TE. Pathogenesis of pulmonary fibrosis in interstitial lung disease. Alveolar macrophage PDGF(B) gene activation and up-regulation by interferon gamma. Am Rev Respir Dis. 1991 Jan; 143(1):167-73.
        View in: PubMed
      174. Aguayo SM, King TE, Waldron JA, Sherritt KM, Kane MA, Miller YE. Increased pulmonary neuroendocrine cells with bombesin-like immunoreactivity in adult patients with eosinophilic granuloma. J Clin Invest. 1990 Sep; 86(3):838-44.
        View in: PubMed
      175. Goldstein RA, Rohatgi PK, Bergofsky EH, Block ER, Daniele RP, Dantzker DR, Davis GS, Hunninghake GW, King TE, Metzger WJ, et al. Clinical role of bronchoalveolar lavage in adults with pulmonary disease. Am Rev Respir Dis. 1990 Aug; 142(2):481-6.
        View in: PubMed
      176. Buschman DL, Waldron JA, King TE. Churg-Strauss pulmonary vasculitis. High-resolution computed tomography scanning and pathologic findings. Am Rev Respir Dis. 1990 Aug; 142(2):458-61.
        View in: PubMed
      177. Tazelaar HD, Myers JL, Drage CW, King TE, Aguayo S, Colby TV. Pulmonary disease associated with L-tryptophan-induced eosinophilic myalgia syndrome. Clinical and pathologic features. Chest. 1990 May; 97(5):1032-6.
        View in: PubMed
      178. Panos RJ, Mortenson RL, Niccoli SA, King TE. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med. 1990 Apr; 88(4):396-404.
        View in: PubMed
      179. Last JA, King TE, Nerlich AG, Reiser KM. Collagen cross-linking in adult patients with acute and chronic fibrotic lung disease. Molecular markers for fibrotic collagen. Am Rev Respir Dis. 1990 Feb; 141(2):307-13.
        View in: PubMed
      180. Aguayo SM, Kane MA, King TE, Schwarz MI, Grauer L, Miller YE. Increased levels of bombesin-like peptides in the lower respiratory tract of asymptomatic cigarette smokers. J Clin Invest. 1989 Oct; 84(4):1105-13.
        View in: PubMed
      181. Newman LS, Kreiss K, King TE, Seay S, Campbell PA. Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. Am Rev Respir Dis. 1989 Jun; 139(6):1479-86.
        View in: PubMed
      182. Leff JA, King TE. Cavitary lung disease with skin lesions. Chest. 1989 Feb; 95(2):457-8.
        View in: PubMed
      183. King TE. Bronchiolitis obliterans. Lung. 1989; 167(2):69-93.
        View in: PubMed
      184. Savici D, Campbell PA, King TE. Bronchoalveolar macrophages from patients with idiopathic pulmonary fibrosis are unable to kill facultative intracellular bacteria. Am Rev Respir Dis. 1989 Jan; 139(1):22-7.
        View in: PubMed
      185. Badesch DB, King TE, Schwarz MI. Acute eosinophilic pneumonia: a hypersensitivity phenomenon? Am Rev Respir Dis. 1989 Jan; 139(1):249-52.
        View in: PubMed
      186. King TE, Savici D, Campbell PA. Phagocytosis and killing of Listeria monocytogenes by alveolar macrophages: smokers versus nonsmokers. J Infect Dis. 1988 Dec; 158(6):1309-16.
        View in: PubMed
      187. Dunn TL, Watters LC, Hendrix C, Cherniack RM, Schwarz MI, King TE. Gas exchange at a given degree of volume restriction is different in sarcoidosis and idiopathic pulmonary fibrosis. Am J Med. 1988 Aug; 85(2):221-4.
        View in: PubMed
      188. Willcox M, Kervitsky A, Watters LC, King TE. Quantification of cells recovered by bronchoalveolar lavage. Comparison of cytocentrifuge preparations with the filter method. Am Rev Respir Dis. 1988 Jul; 138(1):74-80.
        View in: PubMed
      189. Robinson PC, Watters LC, King TE, Mason RJ. Idiopathic pulmonary fibrosis. Abnormalities in bronchoalveolar lavage fluid phospholipids. Am Rev Respir Dis. 1988 Mar; 137(3):585-91.
        View in: PubMed
      190. Shen A, Iseman MD, Waldron JA, King TE. Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous estrogens. Chest. 1987 May; 91(5):782-5.
        View in: PubMed
      191. Watters LC, Schwarz MI, Cherniack RM, Waldron JA, Dunn TL, Stanford RE, King TE. Idiopathic pulmonary fibrosis. Pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. Am Rev Respir Dis. 1987 Mar; 135(3):696-704.
        View in: PubMed
      192. Watters LC, King TE, Cherniack RM, Waldron JA, Stanford RE, Willcox ML, Christopher KL, Schwarz MI. Bronchoalveolar lavage fluid neutrophils increase after corticosteroid therapy in smokers with idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1986 Jan; 133(1):104-9.
        View in: PubMed
      193. Watters LC, King TE, Schwarz MI, Waldron JA, Stanford RE, Cherniack RM. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1986 Jan; 133(1):97-103.
        View in: PubMed
      194. Libby LS, King TE, LaForce FM, Schwarz MI. Pulmonary cavitation following pulmonary infarction. Medicine (Baltimore). 1985 Sep; 64(5):342-8.
        View in: PubMed
      195. King TE, Schwarz MI, Mathew M. Waldenström's macroglobulinemia: report of a case with pulmonary involvement and recurrent pneumococcal sepsis after pneumococcal vaccination. J Natl Med Assoc. 1984 Feb; 76(2):184-6, 189.
        View in: PubMed
      196. Good JT, King TE, Antony VB, Sahn SA. Lupus pleuritis. Clinical features and pleural fluid characteristics with special reference to pleural fluid antinuclear antibodies. Chest. 1983 Dec; 84(6):714-8.
        View in: PubMed
      197. Stelzner TJ, King TE, Antony VB, Sahn SA. The pleuropulmonary manifestations of the postcardiac injury syndrome. Chest. 1983 Oct; 84(4):383-7.
        View in: PubMed
      198. King TE, Stelzner TJ, Sahn SA. Cardiac tamponade complicating the postpericardiotomy syndrome. Chest. 1983 Mar; 83(3):500-3.
        View in: PubMed
      199. King TE, Christopher KL, Schwarz MI. Multiple pulmonary chondromatous hamartomas. Hum Pathol. 1982 May; 13(5):496-7.
        View in: PubMed
      200. King TE, Fisher J, Schwarz MI, Patzelt LH. Bilateral hilar adenopathy: an unusual presentation of renal cell carcinoma. Thorax. 1982 Apr; 37(4):317-8.
        View in: PubMed
      201. Kaplan RL, Schocket AL, King TE, Maulitz RM, Good JT, Stanford RE, Sahn SA. A model of immune complex-mediated pleuropulmonary injury; evidence of deposition of circulating immune complexes in the lung. Am J Pathol. 1980 Jul; 100(1):115-30.
        View in: PubMed
      202. King TE, Schwarz MI, Dreisin RE, Pratt DS, Theofilopoulos AN. Circulating immune complexes in pulmonary eosinophilic granuloma. Ann Intern Med. 1979 Sep; 91(3):397-9.
        View in: PubMed
      Back to TOP